Ono Pharmaceutical (OTCMKTS:OPHLF) Sees Unusually-High Trading Volume – Time to Buy?

Ono Pharmaceutical Co. (OTCMKTS:OPHLF) saw unusually-high trading volume on Thursday . Approximately 458 shares traded hands during trading, an increase of 4% from the previous session’s volume of 440 shares.The stock last traded at $16.10 and had previously closed at $16.5450.

Ono Pharmaceutical Stock Up 16.0%

The business’s fifty day simple moving average is $14.13 and its two-hundred day simple moving average is $12.49. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.02 and a quick ratio of 2.56. The company has a market cap of $8.77 billion, a PE ratio of 20.98 and a beta of 0.25.

Ono Pharmaceutical (OTCMKTS:OPHLF) last released its earnings results on Monday, February 2nd. The company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.29 by $0.11. Ono Pharmaceutical had a return on equity of 7.76% and a net margin of 12.29%.The company had revenue of $892.70 million during the quarter, compared to analysts’ expectations of $727.58 million.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research?based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.